Relay Therapeutics, Inc. (RLAY)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $17.36
- As of
Kresmion compiles this page from RLAY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Relay Therapeutics, Inc. (RLAY): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
See the full RLAY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RLAY on one page. Preview it with sample data, then open it live with a free account.
Preview the RLAY dossierActive signals for RLAY
- highCONSENSUS_BUY
4 tracked funds increased RLAY this 2026Q2, institutional consensus
- highinsider_cluster_sell
2 insiders at RLAY sold $116.5M this week
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +415% to RLAY (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +131% to RLAY (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +335% to RLAY (2026Q2)
FREE, NO ACCOUNT
Every signal on RLAY, as it fires
You are seeing 5 of 11 signals recorded on RLAY since 2026-05-24.
The five above landed across 3 days. The other 6 were recorded on 2 other days. 6 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RLAY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 75943R102 · 2026Q2 | $13.1M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 75943R102 · 2026Q2 | $11.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 75943R102 · 2026Q2 | $8.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 75943R102 · 2026Q2 | $3.6M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RLAY
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RLAY against its peers
RLAY's operating margin of -1971.6% ranks in the 23rd percentile of 14 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RLAY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 15.4M USD | 219M USD | 36 | 17 |
| Operating margin | -1971.6% | -13.0% | 23 | 14 |
| Net margin | -1800.6% | -17.0% | 23 | 14 |
| Return on equity | -48.8% | -29.9% | 34 | 24 |
| 1 year | 176.9% | 28.0% | 93 | 19 |
Peers (24): CPRX, TNGX, TLX, VCYT, VKTX, LEGN, EWTX, XENE, IDYA, DNTH, ACAD, GRTX, ARQT, CELC, TVTX, DNLI, DYN, DFTX, RCUS, ELVN, SRRK, CRSP, APLS, COGT. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RLAY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RLAY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RLAY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.